34.15 USD
▲+1.50+4.59%
盘后 34.80 +1.90%
2026-09-15
市值
$19.84B
市盈率
25.18
EPS
1.26
股息率
—
52 周区间
23.62 – 35.43
成交量
3.09M
Beta
0.70
目标价
38.86
52W 低 23.6252W 高 35.43
价格走势
公司简介
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell n...